{"id":"W4289985859","doi":"10.3390/curroncol29080434","title":"Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Sorafenib; Medicine; Regorafenib; Lenvatinib; Nivolumab; Ramucirumab; Atezolizumab; Cabozantinib; Ipilimumab; Bevacizumab; Oncology; Internal medicine; Hepatocellular carcinoma; Pembrolizumab; Renal cell carcinoma; Cancer; Immunotherapy; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005030807,0.0005635361,0.004098364,0.0003281723,0.0003039209,0.000009747204,0.0001931954,0.0003381779,0.0006640957],"category_scores_gemma":[0.000258652,0.000421174,0.0005983556,0.0002295421,0.0002514953,0.00002984877,0.0002144492,0.0006479705,0.00003499753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001995946,"about_ca_system_score_gemma":0.002243989,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001847406,"about_ca_topic_score_gemma":0.00003078907,"domain_scores_codex":[0.9971622,0.0003089535,0.000806941,0.000822262,0.0002470593,0.0006525822],"domain_scores_gemma":[0.9967341,0.001906097,0.0003644509,0.0005286584,0.00009077061,0.0003759085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002116246,0.001159318,0.002251738,0.01539539,0.0003764217,0.0001717938,0.0002217329,6.519976e-8,1.198824e-7,0.0001378349,0.002757681,0.9773163],"study_design_scores_gemma":[0.005147458,0.004431458,0.00002223854,0.0008667568,0.005156864,0.0003747919,0.00007738388,0.0001912518,5.874498e-7,0.0001054551,0.9833263,0.0002994313],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00120467,0.9893972,0.00006188407,0.0003908709,0.00108728,0.005771006,0.0002608715,0.00005015937,0.001776096],"genre_scores_gemma":[0.00007368899,0.9880786,0.0005535544,0.00004219691,0.0005557505,0.006272635,0.001587922,0.00008084309,0.002754817],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9805686,"threshold_uncertainty_score":0.999824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2562370346035748,"score_gpt":0.4813477896404419,"score_spread":0.2251107550368671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}